The 24D2 monoclonal antibody specifically recognizes CD340 which is also known as Human epidermal growth factor receptor 2 (HER-2 or HER2), Neu (neuro/glioblastoma derived oncogene homolog), or Metastatic lymph node gene 19 protein (MLN19). CD340 (HER-2) is a ~185 kDa type I transmembrane glycoprotein that is encoded by ERBB2 (erb-b2 receptor tyrosine kinase 2) and belongs to the ERBB family of receptor tyrosine kinases that includes EGFR, HER3, and HER4. Although CD340 (HER-2) has no identified direct-binding ligand, it can form heterodimers with other ligand-bound ERBB family members. CD340 (HER-2) helps activate intracellular signaling pathways including mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI-3K) through its cytoplasmic tyrosine kinase-containing region. CD340 (HER-2) is expressed by bone marrow mesenchymal stem cells. It is overexpressed and plays a significant role in the development of multiple human cancers including some leukemias, neuroblastomas, and carcinomas of the breast, ovary, cervix, colon, and lung.
The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.